Ustekinumab in adolescent patients age 12 to 17Â years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

In this patient population (12-17 years), the standard ustekinumab dose provided response comparable to that in adults with no unexpected AEs through 1 year.